OSE Immunotherapeutics has reported positive top-line data from the investigator-sponsored Phase II trial assessing Tedopi in combination with FOLFIRI (a three-drug chemotherapy regimen made up of folinic acid, fluorouracil and irinotecan) in patients with pancreatic cancer (advanced or metastatic

12 Mar 2025
Tedopi shows promise in pancreatic cancer

Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Tedopi shows promise in pancreatic cancer
- Published:
12 Mar 2025 -
Author:
Jyoti Prakash, CFA | Arron Aatkar, PhD -
Pages:
2 -
OSE Immunotherapeutics has reported positive top-line data from the investigator-sponsored Phase II trial assessing Tedopi in combination with FOLFIRI (a three-drug chemotherapy regimen made up of folinic acid, fluorouracil and irinotecan) in patients with pancreatic cancer (advanced or metastatic